News
Abzena announces successful technical transfer of Synaffix GlycoConnect™ Antibody Drug Conjugates (ADCs) technology to enable use in client projects Tweet this Jonathan Goldman, MD, Abzena CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback